Updates in ER+ breast cancer from SABCS 2024 include the EMBER-3 trial of novel oral SERD imlunestrant, PATINA trial results, and updated analysis from TAILORx, as reported by Dr Harold Burstein.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback